BioSenic to Hold Annual Meeting on June 14, 2023


biothenic

biothenic

Regulated Information

Preliminary documents for the annual meeting are now available on the company’s website. website

Belgium, Montsanghibert, in May 15th day2023 7.00:00 am Central European Time – biothenic (Euronext Brussels and Paris: BIOS)The company, a clinical-stage company specializing in severe autoimmune and inflammatory diseases and cell repair, announced to shareholders and holders of the Company’s registered stock acquisition rights and registered convertible bonds on Wednesday, June 14, 2023, I will invite you to the annual general meeting to be held from the 4th. 00:00 CEST, Osborne Clark Office, Bastion Tower, Place du Champ de Mars 5, 1050 Brussels, Belgium.

The notice of the meeting, including the day’s agenda and voting motions, will be published today in the Belgian Gazette and in the Belgian newspaper La Livre.

Documentation and preliminary information about these meetings are available and can be found on the BioSenics website section. Investor / annual general M.eatcomply with applicable laws and regulations.
You can also pick up your documents free of charge with a simple request by emailing generalassembly@biosenic.com or by calling +32 (0)493 09 73 66. Documents are also available at the company’s headquarters, Rue Granbonpré 11, Building. H, 1435 Mont Saint Guibert, Belgium.

almost biothenic

biothenic is a leading biotechnology company specializing in the development of clinical assets.I), allogeneic cell therapy platform ALLOB, and (ii) arsenic trioxide (ATO) platform. The main target indications for this platform include graft-versus-host disease (GvHD), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and high-risk tibial fractures.
After the merger in October 2022, biothenic combines the strategic positioning and strengths of Medcenic and bone therapeutics. The merger also provides Biocenic with an innovative cell therapy platform and a potent portfolio of products for tissue repair and protection with an entirely new arsenal of anti-inflammatory and anti-autoimmune agents that harness the immunomodulatory properties of ATO/OATO. It becomes possible to add IPs.
biothenic Based in LouvainlaNeuve Science park in Mont-Saint-Guibert, Belgium. For more information, please refer to the following URL: http://www.biosenic.com.

almost biothenic technology platform

biosynics This technology is based on two main platforms.

1) The allogeneic cell and gene therapy platform was developed by. biothenic It uses differentiated bone marrow-derived mesenchymal stromal cells (MSCs) and can be stored for hospital use. The investigational drug ALLOB represents a unique approach to organ repair, particularly bone regeneration, by converting undifferentiated stromal cells from healthy donors into osteogenic cells at the site of injury after a single local injection. . These cells biosynics Scalable manufacturing process. Following approval of the CTA by European regulators, biothenic has initiated patient recruitment for a Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures using an optimized production process. After successful initial safety and efficacy trials (Phase 1/Phase 2), ALLOB is now conducting a randomized dual trial in patients with high-risk tibial fractures using an optimized manufacturing process. It is being evaluated in a blinded, placebo-controlled Phase 2b study.a) ON Fractured long bones with delayed union. Patient recruitment was suspended with her 57 patients in late February 2023, with new rules allowing for statistical analysis. biothenic The primary results of this trial are expected by mid-2023, much earlier than expected in the original protocol.
2) Arsenic Trioxide (ATO) platform developed by Medcenic. ATO’s immunomodulatory properties demonstrate a dual, fundamental effect on the cells of the immune system. The first effect is an increase in cellular oxidative stress in activated B. T. Or to the point where other cells of the innate/adaptive immune system enter a cell death program (apoptosis) and are eliminated. A second effect is its potent immunomodulatory properties against several pro-inflammatory cytokines involved in inflammatory or autoimmune cell pathways. One direct application is its use in tumor immunology to treat her GvHD (graft-versus-host disease) in its chronic, established stage. GvHD is one of the most common and clinically significant complications affecting long-term survival of allogeneic hematopoietic stem cell transplantation (thx-SCT). GvHD is primarily mediated by the transplanted immune system and can cause severe multi-organ damage. Medcenic Successful Intravenous Phase II Trial Receives Orphan Drug Designation Status by FDA and EMA for Arsenic Trioxide, International Phase III Confirmatory Study with New IP Protected Oral Agent (OATO) heading to Formulated. Moderate to severe systemic lupus erythematosus (SLE) is also a target of choice using the same oral formulation. ATO was found in several affected organs (skin, mucous membrane and gastrointestinal tract) IIa study.
Additionally, systemic sclerosis is part of the clinical pipeline. biothenic. Preclinical studies on relevant animal models have yielded positive results. This provides a good basis for initiating a Phase II clinical protocol for this serious disease that adversely affects the skin. lung or angiogenesis, and currently there are no really effective treatments.

In addition, biothenic Developing next-generation improved off-the-shelf products viscous supplement, JTA-004 consists of a unique combination of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid, and a fast-acting pain reliever. JTA-004 is intended to provide additional lubrication and protection to cartilage in arthritic joints to reduce pain (OA) and inflammation in osteoarthritis. In March 2023, after new OA subtypes have been identified, biothenic published a new post hoc analysis of the phase III JTA-004 trial in knee OA, with positive action for the most severely affected patient population. This new post-hoc analysis may change the therapeutic profile of the molecule and stratify patients towards newly optimized phase III clinical studies. biothenicdoes not intend to allocate R&D resources to support the clinical development of JTA-004 and will continue to focus its R&D activities on the development of its autoimmune (ATO) and cell therapy (ALLOB) platforms, but currently We are looking for cooperation with research institutes. Potential partners will consider options for future development of JTA-004 based on this new post-mortem analysis.

For more information, please contact:

biothenic SA
public relations Francois LeaguerPh.D., CEO
Phone: +33 (0)671 73 31 59
investorrelations@biosenic.com

Inquiries from Belgian media and investors:
be public
Bert Bousley
Phone: +32 (0)488 40 44 77
bert.bouserie@bepublicgroup.be

Inquiries from overseas media:
IB Communications
Neal Hunter / Michelle Boxall
Phone: +44 (0)20 8943 4685
neil.hunter@ibcomms.agency / michelle@ibcomms.agency

Inquiries from the French media:
new cap media
Annie Florence Royer
Phone: +33 (0)1 44 71 00 12
afloyer@newcap.fr

Inquiries from French investors:
Holy city system actifin
Ghyslaine Gaspalette
Phone: +33 (0)1 56 88 11 22
ggasparetto@actifin.fr

Certain statements, beliefs and opinions in this press release are forward-looking and reflect the current expectations and projections of the Company or, as appropriate, its directors, regarding future events. By their nature, forward-looking statements include: Several Risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied in the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the results and financial impact of any plans or events described herein. Various factors such as, but not limited to, changes in demand. competition and technology could cause actual events, performance or results to differ materially from anticipated developments. Forward-looking statements contained in this press release regarding past trends or activities should not be construed as representations that such trends or activities will continue in the future. As a result, we expressly disclaim any obligation or commitment to update or revise any forward-looking statements in this press release. as a result changes in expectations or changes in events, conditions, assumptions or circumstances upon which these forward-looking statements are based; Neither the Company, nor its advisors or representatives, nor its subsidiaries, nor their officers or employees, warrants that the assumptions underlying such forward-looking statements are error-free, nor do any forward-looking statements. assumes no liability for the future accuracy of Statements contained in this press release or actual occurrence of anticipated developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *